- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05679830
The Effects of CBD Isolate on Menstrual-Related Symptoms
A Randomized, Open-Label Trial on the Effects of Cannabidiol Isolate on Menstrual-Related Symptoms
The goal of this open-label clinical trial is to compared two different doses for treating menstrual-related symptoms in individuals who experience regular menstrual cycles (occurring for 4-8 days every 21-28 days). The main question it aims to answer is:
(1) if there are changes in menstrual-related symptoms from baseline compared to all 3-months of cannabidiol (CBD) isolate consumption.
Participants will complete a monthly baseline measure after they stop menstruating followed by taking CBD twice daily (BID) for five days for three menstrual cycles and complete the same measures. Researchers will compare 160mg of daily CBD isolate to 320mg of CBD isolate to see if there are differential effects on menstrual-related symptoms (MRS).
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Virginia
-
Harrisonburg, Virginia, United States, 22801
- James Madison University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participant is at least 18 years old.
- Participant is willing and able to provide informed consent and participate in the study for 4 months.
- Participant experiences a regular period (occurring every 21-38 days and lasting between 4-8 days).
- Participant is diagnosed with Pre-menstrual Dysphoric Disorder or scores at least '30' on the Menstrual-Related Symptom Questionnaire
- Participant is willing to begin tracking their periods and menstrual symptoms for the duration of the study
- Participant agrees to abide by all study restrictions and comply with all study procedures.
Exclusion Criteria:
- Participant has a known history of significant allergic condition, significant hypersensitivity to CBD, or allergic reaction to cannabis, cannabinoid medications, or excipients of the drug product.
- Participant has been exposed to any investigational drug or device < 30 days prior to screening or plans to take another investigational drug at any time during the study.
- Participant has self-reported using cannabis, synthetic cannabinoid or cannabinoid analogue (e.g., dronabinol, nabilone), synthetic cannabinoid receptor agonist (e.g., spice, K2), or any CBD or Tetrahydrocannabinol (THC)-containing product within 30 days of screening or during the study.
- Participant has a current or past primary Diagnostic and Statistical Manual of Mental Disorders (DSM)-5 diagnosis that the Investigator(s) determines would interfere in treatment or interfere in evaluation of the study treatment (e.g., current psychotic disorder).
- Participant is currently prescribed medications with known THC- or CBD- interactions (e.g., warfarin, clobazam, valproic acid, phenobarbital, Mammalian target of rapamycin (mTOR) inhibitors, oral tacrolimus).
- Participant is trying to get pregnant.
- Participant is pregnant.
- Participant has a history of suicide attempt in the last year.
- Participant endorses current suicidal plan and intent during screening.
- Any other significant disease or disorder which, in the opinion of the investigator, may either put the student at risk because of participation in the study, may influence the result of the study, or affect the student's ability to participate in the study.
- Participant has a BMI of underweight (18 kg/m2 and below) or obese (30 kg/m2 and above).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: 160mg Cannabidiol Isolate
320mg of CBD Isolate BID for 5 days every month starting the day that participants believed they were having menstrual-related symptoms (MRS).
|
Cannabidiol is a non-psychoactive cannabinoid obtained from the cannabis plant.
|
Experimental: 320mg Cannabidiol Isolate
160mg of CBD Isolate BID for 5 days every month starting the day that participants believed they were having menstrual-related symptoms (MRS).
|
Cannabidiol is a non-psychoactive cannabinoid obtained from the cannabis plant.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Menstrual-Related Symptoms Questionnaire (MRSQ)
Time Frame: 1 menstrual cycle/1 month
|
Change in menstrual-related symptoms from baseline scores as measured by the MRSQ every cycle for three cycles.
Scores range from 26-104, with higher scores representing greater severity of symptoms.
|
1 menstrual cycle/1 month
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Jessica G Irons, PhD, James Madison University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- MRS
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Menstrual Discomfort
-
University of FloridaLallemand Health SolutionsActive, not recruitingMenstrual DiscomfortUnited States
-
Riphah International UniversityUniversity of LahoreCompletedMenstrual Discomfort | FemalesPakistan
-
Hiroshima UniversityRecruitingMenstrual Discomfort | Occupational Problems | Work-Related ConditionBangladesh
-
Semaine HealthCitruslabsCompletedMenstrual Pain | Menstrual DiscomfortUnited States
-
Your Super, INC.CitruslabsCompletedMenstrual Pain | PMS | Menstrual DiscomfortUnited States
-
Premama Inc.CitruslabsWithdrawnMenstrual Irregularity | Menstrual Pain | Hormone Disturbance | PMS | Menstrual Discomfort
-
Tufts Medical CenterTufts UniversityRecruitingPatient Empowerment | Autistic Spectrum Disorder | Menstrual DiscomfortUnited States
-
University of Illinois at Urbana-ChampaignUnknownPolycystic Ovary Syndrome | Endometriosis | Dysmenorrhea | Menstrual Pain | Fibroid | Menstrual Discomfort | Dysmenorrhea Secondary | Secondary Dysmenorrhea | Menstrual DisorderUnited States
-
Cukurova UniversityCompletedMenstrual Discomfort | Dysmenorrhea Primary | Relaxation AbnormalityTurkey
-
Taipei Medical University WanFang HospitalCompletedIrregular Menstrual Cycle | Regular Menstrual CycleTaiwan
Clinical Trials on Cannabidiol
-
University of Colorado, BoulderRecruitingDepression | Pain | Sleep | AnxietyUnited States
-
University of Colorado, BoulderNot yet recruiting
-
University of Colorado, BoulderNational Institute on Drug Abuse (NIDA)Not yet recruitingCannabis Use Disorder
-
Marius HenriksenCompleted
-
Elena PopeAvicanna IncWithdrawnPain | Epidermolysis Bullosa | ItchCanada
-
Johns Hopkins UniversityNational Institute on Drug Abuse (NIDA)RecruitingTobacco Use | Tobacco Smoking | Tobacco Use Disorder | Tobacco Use Cessation | Tobacco DependenceUnited States
-
Zynerba Pharmaceuticals, Inc.Enrolling by invitationFragile X SyndromeUnited States, United Kingdom, New Zealand, Australia
-
Yale UniversityNational Institute on Drug Abuse (NIDA); VA Connecticut Healthcare SystemRecruiting
-
University of Northern ColoradoCompleted
-
Pure GreenCompletedMusculoskeletal PainUnited States